Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Neutral 0

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

AI-generated analysis

πŸ“‰ Gilead Sciences (GILD) shares dropped -1.1% over the past month, significantly underperforming the S&P 500's +6% gain and the unchanged Medical-Biomedical industry sector.

πŸ’‘ Analysts at Zacks prioritize future earnings projection changes over market rumors as the primary driver for stock fair value and price direction.

πŸ“ˆ Gilead is projected to earn $1.89 per share this quarter, a 4.4% year-over-year increase with minimal recent revision (-0.3%).

πŸ’° The consensus full-year earnings estimate stands at $8.63 (up 5.9% YoY), while the next fiscal year's projection is $9.62 (up 11.4% YoY).

πŸ“‰ Recent earnings and revenue estimates show slight negative revisions over the last 30 days for both current and forward periods.

πŸ” The Zacks Rank #3 (Hold) rating suggests Gilead is expected to perform in line with the broader market rather than significantly outperforming or underperforming.

πŸ’΅ Reported quarterly revenues of $7.93 billion beat estimates by 4.63%, while EPS of $1.86 also surpassed expectations by 1.64%.

πŸ† Historically, Gilead has beaten consensus estimates for earnings and revenue in three of its last four quarters respectively.

πŸ’Έ Forward sales growth is expected at 3.4% this quarter, 2.4% for the current fiscal year, and 7.3% for the next fiscal year.

βš–οΈ Gilead holds a Zacks Value Style Score of B, indicating it is currently trading at a discount to its industry peers based on valuation multiples.

πŸ“Š The company's intrinsic value assessment considers whether its price reflects both current business performance and future growth prospects.

🧭 While fundamental data supports holding the stock, the Zacks Rank #3 implies limited near-term upside potential despite recent positive surprise history.

Bullish Signals
  • Gilead reported revenues of $7.93 billion in the last quarter, beating the consensus estimate of $7.57 billion by a +4.63% surprise.
  • The company's EPS of $1.86 also exceeded the analyst expectations with a positive +1.64% surprise against the consensus.
  • Over the past four quarters, Gilead surpassed both consensus EPS and revenue estimates three times each, demonstrating consistent performance.
  • Consensus earnings estimates for the current fiscal year show a healthy +5.9% year-over-year growth trajectory at $8.63 per share.
  • Forward-looking estimates indicate an expected +11.4% increase in earnings for the next fiscal year compared to a year ago.
  • Revenue growth projections remain positive with estimates of +3.4%, +2.4%, and +7.3% for the current quarter and two subsequent fiscal years respectively.
  • Gilead is graded 'B' on the Zacks Value Style Score, indicating it is trading at a discount to its peers.
Risk Factors
  • Shares of Gilead Sciences (GILD) are down -1.1% over the past month, lagging significantly behind the Zacks S&P 500 composite's +6% gain.
  • The stock carries a Zacks Rank #3 (Hold), which suggests it may only perform in line with the broader market rather than outperforming.
  • Consensus earnings estimates have declined over the past month for every period analyzed: -0.3% over the last 30 days for current and fiscal year, and -0.1% for the next fiscal year.
  • Despite a recent revenue beat, the company's Zacks Value Style Score is graded 'B', indicating it trades at a discount to peers but still lacks strong bullish valuation signals.
  • Research Director Sheraz Mian warns that not all of Zacks' picks are guaranteed winners, highlighting the risk of loss in their recommendations.
Full Analysis
Gilead Sciences (GILD) has recently seen increased attention as a trending stock, prompting an analysis of its factors affecting near-term performance. Over the past month, shares have declined by 1.1%, lagging behind the Zacks S&P 500 composite's gain of 6%, while the broader biomedical and genetics industry has remained unchanged. The core investment thesis here relies on the correlation between earnings estimate revisions and short-term stock price movements, with Gilead currently holding a Zacks Rank #3 (Hold) rating due to modest recent changes in consensus estimates. Financial projections indicate that Gilead is expected to post current quarter earnings of $1.89 per share, representing a 4.4% year-over-year increase. For the current fiscal year, the consensus estimate stands at $8.63, marking a 5.9% increase from the prior year, while next fiscal year's estimate is projected at $9.62, a 11.4% rise. Revenue expectations align with these earnings figures, with the current quarter estimated at $6.89 billion (a 3.4% YoY increase), and annual forecasts of $30.15 billion and $32.36 billion for the current and next fiscal years respectively, showing growth rates of 2.4% and 7.3%. The company's recent financial track record has been positive relative to expectations; Gilead reported last quarter revenues of $7.93 billion, surpassing the consensus estimate by 4.63%, with EPS of $1.86 exceeding estimates by 1.64%. Historically, the company has beaten earnings and revenue estimates three times out of the last four quarters. However, valuation metrics place Gilead in a neutral stance; it received a Zacks Value Style Score of B, indicating it trades at a discount to its peers, yet this does not translate into immediate price upside potential given the current Hold rating, suggesting the stock may perform in line with the broader market in the near term.